Wockhardt breaks ground in MENA region with new Dubai factory

30 July 2018
drugs_pills_tablets_big

India-based generic drug manufacturer Wockhardt (BSE: 532300) is making its entry into the Middle East and North Africa (MENA) region with a new facility in Dubai.

The Mumbai-headquartered firm, which has manufacturing plants in India, the UK, Ireland, France and the USA, says the $40-million site will be used to make antibiotics for export, primarily to mature markets in Europe and the USA.

The self-contained factory, spread over 10,000 square meters, will focus initially on developing a therapy targeting so-called ‘superbugs’.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics